Home/ Stocks/ CRSP

CRISPR Therapeutics AG

CRSP XNAS

$59.20 -1.57 (-2.58%) ▼ 15-min delayed

Open

$58.51

High

$60.33

Low

$57.57

Volume

1.23M

Market Cap

$5.98B

About CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 393 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$1.46M	$-122,931,000	$-1.28
FY 2025	$3.51M	$-581,599,000	$-6.47
Q3 2025	$889.0K	$-106,441,000	$-1.17
Q2 2025	$892.0K	$-208,549,000	$-2.40

Related Market News

No specific coverage for CRSP yet. Check out our latest market news or earnings calendar.

Get CRSP Alerts

Stay ahead with breaking news, price alerts, and expert analysis on CRISPR Therapeutics AG.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.